Search review questions

Intensive diet plus exercise Description: direct medical costs per participant · people at increased risk for developing type 2 diabetes

All‐cause mortality (N) · people at increased risk for developing type 2 diabetes

Incidence of type 2 diabetes mellitus (N) Diagnostic criteria: 2 trials applied the WHO 1999 criteria (FPG ≥7.0 mmol/L and/or a 2‐hour glucose ≥11.1 mmol/L after a 75 g OGTT) (IDPP‐1 2006; Zhao 2013) · people at increased risk for developing type 2 diabetes

Serious adverse events · people at increased risk for developing type 2 diabetes

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

Non‐fatal myocardial infarction/stroke · people at increased risk for developing type 2 diabetes

Health‐related quality of life · people at increased risk for developing type 2 diabetes

Socioeconomic effects Description: direct medical costs per participant · people at increased risk for developing type 2 diabetes

Intensive diet plus exercise · people at increased risk for developing type 2 diabetes

Sulphonylurea · people at increased risk for developing type 2 diabetes

Acarbose · people at increased risk for developing type 2 diabetes

Thiazolidinediones · people at increased risk for developing type 2 diabetes

Placebo or diet and exercise Diagnostic criteria: 3 trials applied the WHO 1985 criteria (FPG <7.8 mmol/L and 2‐hour glucose ≥7.8 mmol/L and <11.1 mmol/L after a 75 g OGTT) (Fang 2004; Li 1999; Lu 2002). 5 trials applied the WHO 1999 criteria (FPG... · people at increased risk for developing type 2 diabetes

Intensive diet plus exercise Diagnostic criteria: 1 trial applied the WHO 1985 criteria (FPG < 7.8 mmol/L and 2‐hour glucose ≥ 7.8 mmol/L and < 11.1 mmol/L) (Fang 2004) · people at increased risk for developing type 2 diabetes

Acarbose Diagnostic criteria: 1 trial applied the WHO 1985 criteria (FPG < 7.8 mmol/L and 2‐hour glucose ≥ 7.8 mmol/L and < 11.1 mmol/L) (Fang 2004). 1 trial applied the WHO 1999 criteria (FPG ≥ 7.0 mmol/L and/or a 2‐hpur glucose ≥ 11.1 mmol/L aft... · people at increased risk for developing type 2 diabetes

Improvement in final adult height (cm)

Adverse events (N)

Health‐related quality of life

Effects on speech (voice frequency)

Effects on cognition(WISC‐R questionnaire)

Effects on psychological status (several questionnaires)

All‐cause mortality

Weight loss (kg) (a) All fluoxetine dosages (b) Fluoxetine 60 mg/d(c) Fluoxetine 40 mg/d(d) Fluoxetine 20 mg/d · overweight or obese adults

Health‐related quality of life · overweight or obese adults

Any adverse event (N) · overweight or obese adults

Anthropometric measurements other than weight loss in kg (BMI reduction measured inkg/m²) · overweight or obese adults

Morbidity: depression (N) · overweight or obese adults

All‐cause mortality · overweight or obese adults

Socioeconomic effects · overweight or obese adults

All‐cause mortality (N)

M + GLP1‐A

M + DPP4‐I

M + thiazolidinedione

M + nateglinide

M + SGLT2‐I

M + DPP4‐I

Health‐related quality of life

M + GLP1‐A

M + DPP4‐I

M + thiazolidinedione

M + nateglinide

M + SGLT2‐I

M + nateglinide

M + nateglinide

Non‐fatal stroke (N)

Permanent RILN palsy (nerves) Definition: injury detected clinically, by laryngoscopy or both, in which the motility of the vocal cords did not recover within 6 months after surgery

Transient RILN palsy (nerves) Definition: injury detected clinically, by laryngoscopy or both, in which the motility of the vocal cords recovered within 6 months after surgery

Health‐related quality of life

Adverse events other than RILN palsy (participants) Definition: transient hypoparathyroidism

Operative time (min) Definition: time from the first skin incision to skin closure